I’ve been quite vocal in my views about the ban on fixed dose combinations on Twitter. So here’s a selection of my key tweets (and some retweets) on the subject. Good way to get a quick summary of the subject while I hem and haw over a longer article (if it ever gets written). Latest tweets on top.
The concern is if they have used the FDC tool to handle a narcotics problem. And whether that will hold up in court https://t.co/wTFzfinihd
— Gauri Kamath (@Apothecurry) March 16, 2016
Would be advisable to not judge the #FDCban based on the cough syrups. There are 300 or more other drugs on that list. @VikasDandekarET
— Gauri Kamath (@Apothecurry) March 16, 2016
To those who say "but DCGI approved this," regulators are allowed to revisit their decision. But of course, they have to defend it. #FDCban
— Gauri Kamath (@Apothecurry) March 16, 2016
There you go https://t.co/5Om2SxeynI
— Gauri Kamath (@Apothecurry) March 16, 2016
Pay attention to exactly which products companies are sueing over. It is likely they have accepted #FDCban on most and challenging only few.
— Gauri Kamath (@Apothecurry) March 16, 2016
Want to see industry fight #FDCban with solid clinical data instead of "we never knew" or "if it's been around this long, it must be fine"
— Gauri Kamath (@Apothecurry) March 16, 2016
Not seeing as much support for industry on #FDCban as for #pioglitazone when leading docs went to town against ban. Waiting. #pharma
— Gauri Kamath (@Apothecurry) March 16, 2016
High Court stays ban on Pfizer’s Corex syrup sale https://t.co/qFsdyLCMe9 #pharma #banneddrugs
— Gauri Kamath (@Apothecurry) March 15, 2016
Impact of Triple Whammy – NLEM, WPI and FDC Ban on Indian Pharma. https://t.co/4bWgJNwg2n pic.twitter.com/pQoWws4eeU
— Anup Soans (@anupsoans) March 14, 2016
Impact of Ban on Therapy Areas and Companies. AIOCD Data pic.twitter.com/m0EnUhFQE2
— Anup Soans (@anupsoans) March 13, 2016
Note that concept of FDC not being challenged. 'Rational' FDCs needed for efficacy/patient compliance/ prevening resistance #bannedfdcs
— Gauri Kamath (@Apothecurry) March 14, 2016
#bannedfdcs suggest sustained pressure from doctors, academia, civil society,media can move the needle on patient safety. *crosses fingers*
— Gauri Kamath (@Apothecurry) March 14, 2016
The shocking thing is not that 300 drugs have been banned. It is that they were sold with impunity for so many years. #bannedfdcs
— Gauri Kamath (@Apothecurry) March 14, 2016
Industry should take haircut for credibility and patient safety. Hair grows back. https://t.co/hO3Z8IkRrn #bannedfdcs
— Gauri Kamath (@Apothecurry) March 14, 2016
Congratulations are in order to @MoHFW_INDIA for cracking down on irrational FDCs. Hope the list holds up in court too. #bannedfdcs
— Gauri Kamath (@Apothecurry) March 14, 2016
List of banned fixed dose combinations. Here's the link. https://t.co/I97bkhhNqC #bannedfdcs Thanks @sunilattavar
— Gauri Kamath (@Apothecurry) March 14, 2016
Apothecurry 
India has perhaps one of the largest portfolio of FDC in the world. The issue is – are FDC synonymous with irrational and against patient interest? In my view some of these FDC were an outcome of traditional Indian Jugaad and innovation and as per clinical need. We tend to judge these FDC from western yardstick – but the West has different reseons for restricting FDC – they see them as product lifestyle extension opportunities so they ” time ” them as per commercial viability etc. This does not take away the need to be discerning and ensure that only rational combinations continue. So no need to go on a witch hunt – let’s just keep the patients safety uppermost in this context
LikeLike